TCF7

Transcription factor 7 (TCF-7) (T-cell-specif · P36402 · TCF7 on Sugi Atlas →

4,323 patent compounds predicted against TCF7, 1,601 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL178745 SCHEMBL178745 1.00 2/20
SCHEMBL4865597 SCHEMBL4865597 1.00 2/20
SCHEMBL4865605 SCHEMBL4865605 1.00 2/20
SCHEMBL13744871 SCHEMBL13744871 1.00 2/20
SCHEMBL13745272 SCHEMBL13745272 0.85 2/20
SCHEMBL12483974 SCHEMBL12483974 0.84 2/20
SCHEMBL12485555 SCHEMBL12485555 0.82 2/20
SCHEMBL1285350 SCHEMBL1285350 0.80 2/20
SCHEMBL8739100 SCHEMBL8739100 0.78 2/20
SCHEMBL2550854 SCHEMBL2550854 0.75 2/20
SCHEMBL13028973 SCHEMBL13028973 0.75 2/20
SCHEMBL747784 SCHEMBL747784 0.74 2/20
SCHEMBL750985 SCHEMBL750985 0.74 2/20
SCHEMBL12485186 SCHEMBL12485186 0.72 2/20
SCHEMBL402163 SCHEMBL402163 0.71 2/20
SCHEMBL13744995 SCHEMBL13744995 0.71 2/20
SCHEMBL12222035 SCHEMBL12222035 0.70 2/20
SCHEMBL749351 SCHEMBL749351 0.69 2/20
SCHEMBL763057 SCHEMBL763057 0.69 2/20
SCHEMBL1286164 SCHEMBL1286164 0.68 2/20

Clinical trials — most relevant to TCF7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Latency in Pulmonary Tuberculosis PHASE3COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans PHASE2NOT_YET_RECRUITING
CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation PHASE1/PHASE2NOT_YET_RECRUITING
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis PHASE2ACTIVE_NOT_RECRUITING
Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas PHASE1SUSPENDED
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Can Gluten-free Diet Prevent the Destruction of Beta-cells During Remission? EARLY_PHASE1UNKNOWN
A Pilot Study of Berberine (Soloways ™) in Patients with Type 2 Diabetes Mellitus Carrying TCF7L2 Polymorphisms nanCOMPLETED
Immunophenotypic Evaluation of IL-7R α in Acute Leukaemia nanUNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Tissue Expression of Krüppel-Like Factors 4 and 7 in Bone Tumors nanRECRUITING
Study on the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family. nanUNKNOWN
Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy nanUNKNOWN
Explore the Role of NLRP7 in the Regulation of Progestereone Induced Decidualization of Human Endometrial Stroma Cells nanCOMPLETED
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
CD7 CAR-T Cells in T-cell Lymphoma/Leukemia nanRECRUITING
Transcriptomic Responses for the Identification of Pathogens nanRECRUITING
LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION nanRECRUITING
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection nanRECRUITING
Effects of Mulberry Juice on Inflammatory Status and Clinical Symptoms in Patients With General Anxiety Disorder nanUNKNOWN
Epithelial Mesenchymal Transition and Periodontitis nanUNKNOWN
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy nanNOT_YET_RECRUITING
CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia nanNOT_YET_RECRUITING
The Role of Dietary Tryptophan on Aryl Hydrocarbon Receptor Activation nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a TCF7 binder may also engage these)

ProteinNameSimilarity
Q00417 1.000 Q00417 →
Q04888 0.998 Q04888 →
P48435 0.996 P48435 →
O55170 0.996 O55170 →
O95096 0.996 O95096 →
Q99958 0.996 Q99958 →
A2D4R4 0.996 A2D4R4 →
A2D4P8 0.995 A2D4P8 →
P78414 0.995 P78414 →
A2D649 0.995 A2D649 →
P57073 0.995 P57073 →
Q9Z1J1 0.995 Q9Z1J1 →
Q92858 0.995 Q92858 →
P14653 0.994 P14653 →
P24899 0.994 P24899 →
P31277 0.994 P31277 →
P17483 0.994 P17483 →
O55144 0.994 O55144 →
Q2VWA4 0.994 Q2VWA4 →
A2T6H5 0.994 A2T6H5 →
P48031 0.994 P48031 →
P57074 0.994 P57074 →
P52954 0.994 P52954 →
A2T7J2 0.994 A2T7J2 →
P19091 0.994 P19091 →
Q8CGW4 0.994 Q8CGW4 →
P43697 0.994 P43697 →
P23813 0.994 P23813 →
P52945 0.994 P52945 →
Q9HCS4 0.993 Q9HCS4 →